Jaydess (Levonorgestrel)

Levonorgestrel released from the IUS binds to progesterone receptors, thickening cervical mucus, suppressing ovulation, and causing endometrial changes that inhibit fertilisation and implantation. The local hormone release ensures effective contraception with minimal systemic exposure.

The prescribed dose is determined by the prescriber. Jaydess contains a total of 13.5 mg of levonorgestrel, released at a low, steady rate over up to three years, providing continuous contraceptive protection without the need for daily dosing.

Jaydess is not intended for use during an existing pregnancy and should be removed if pregnancy occurs. Limited data exist for breastfeeding; clinicians usually weigh benefits against potential risks. Women should discuss individual circumstances with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Jaydess and other levonorgestrel IUS devices such as Mirena have similar mechanisms and efficacy. Jaydess contains 13.5 mg of levonorgestrel and is approved for up to three years of use, whereas some alternatives may have different hormone loads or approved durations, influencing choice based on patient preference and clinical guidelines.

Jaydess should be stored at room temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme temperatures to maintain its integrity until insertion by a qualified clinician.

Jaydess is inserted into the uterine cavity by a trained healthcare professional using a sterile applicator. The procedure is performed in a clinical setting, often after a brief pelvic examination and may involve local anaesthesia or analgesia for patient comfort.

Serious risks include uterine perforation during insertion, device expulsion, pelvic infection (such as pelvic inflammatory disease), and the rare possibility of ectopic pregnancy if contraceptive failure occurs. Patients should seek immediate medical attention for severe abdominal pain, abnormal bleeding or signs of infection.

Jaydess is contraindicated in women who are currently pregnant, have active pelvic infection, known or suspected uterine abnormalities (e.g., large fibroids, septate uterus), unexplained vaginal bleeding, or a known hypersensitivity to levonorgestrel or any component of the device.